These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 22915246)
1. Cost of acute coronary syndrome in Switzerland in 2008. Wieser S; Rüthemann I; De Boni S; Eichler K; Pletscher M; Radovanovic D; Ulle T; Auerbach H Swiss Med Wkly; 2012; 142():w13655. PubMed ID: 22915246 [TBL] [Abstract][Full Text] [Related]
2. Indirect and direct costs of acute coronary syndromes with comorbid atrial fibrillation, heart failure, or both. Ghushchyan V; Nair KV; Page RL Vasc Health Risk Manag; 2015; 11():25-34. PubMed ID: 25565859 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland. Gasche D; Ulle T; Meier B; Greiner RA Swiss Med Wkly; 2013; 143():w13851. PubMed ID: 24089294 [TBL] [Abstract][Full Text] [Related]
4. Resource consumption and healthcare costs of acute coronary syndrome: a retrospective observational administrative database analysis. Roggeri A; Gnavi R; Dalmasso M; Rusciani R; Giammaria M; Anselmino M; Roggeri DP Crit Pathw Cardiol; 2013 Dec; 12(4):204-9. PubMed ID: 24240551 [TBL] [Abstract][Full Text] [Related]
5. The Societal Costs of Schizophrenia in Switzerland. Pletscher M; Mattli R; von Wyl A; Reich O; Wieser S J Ment Health Policy Econ; 2015 Jun; 18(2):93-103. PubMed ID: 26231000 [TBL] [Abstract][Full Text] [Related]
6. [Morbi-mortality and use of recourses after acute coronary syndrome in a Spanish population]. Sicras-Mainar A; Fernández de Bobadilla J; Navarro-Artieda R; Martín I; Varela-Moreno C Rev Clin Esp; 2011 Dec; 211(11):560-71. PubMed ID: 22088667 [TBL] [Abstract][Full Text] [Related]
7. Burden of illness imposed by severe sepsis in Switzerland. Schmid A; Pugin J; Chevrolet JC; Marsch S; Ludwig S; Stocker R; Finnern H Swiss Med Wkly; 2004 Feb; 134(7-8):97-102. PubMed ID: 15106026 [TBL] [Abstract][Full Text] [Related]
8. Acute coronary syndromes in Europe: 1-year costs and outcomes. Taylor MJ; Scuffham PA; McCollam PL; Newby DE Curr Med Res Opin; 2007 Mar; 23(3):495-503. PubMed ID: 17355731 [TBL] [Abstract][Full Text] [Related]
9. Determinants of costs and the length of stay in acute coronary syndromes: a real life analysis of more than 10,000 patients. Bramkamp M; Radovanovic D; Erne P; Szucs TD Cardiovasc Drugs Ther; 2007 Oct; 21(5):389-98. PubMed ID: 17805954 [TBL] [Abstract][Full Text] [Related]
10. Fondaparinux versus enoxaprin in the management of acute coronary syndromes in Switzerland: A cost comparison analysis. Kossovsky M; Keller PF; Mach F; Gaspoz JM Swiss Med Wkly; 2012; 142():w13536. PubMed ID: 22430741 [TBL] [Abstract][Full Text] [Related]
11. The cost of inpatient death associated with acute coronary syndrome. Page RL; Ghushchyan V; Van Den Bos J; Gray TJ; Hoetzer GL; Bhandary D; Nair KV Vasc Health Risk Manag; 2016; 12():13-21. PubMed ID: 26893568 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes. Schwenkglenks M; Brazier JE; Szucs TD; Fox KA Value Health; 2011 Jan; 14(1):24-33. PubMed ID: 21211483 [TBL] [Abstract][Full Text] [Related]
13. Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Europe. Kotseva K; Gerlier L; Sidelnikov E; Kutikova L; Lamotte M; Amarenco P; Annemans L Eur J Prev Cardiol; 2019 Jul; 26(11):1150-1157. PubMed ID: 30955367 [TBL] [Abstract][Full Text] [Related]
14. Costs and quality of life of multiple sclerosis in Switzerland. Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338 [TBL] [Abstract][Full Text] [Related]
15. Health and cost consequences of early versus late invasive strategy after thrombolysis for acute myocardial infarction. Bøhmer E; Kristiansen IS; Arnesen H; Halvorsen S Eur J Cardiovasc Prev Rehabil; 2011 Oct; 18(5):717-23. PubMed ID: 21450598 [TBL] [Abstract][Full Text] [Related]
16. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results. Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362 [TBL] [Abstract][Full Text] [Related]
17. Antithrombotic Therapy and Direct Medical Costs in Patients with Acute Coronary Syndrome in Shanghai, China. Guo JJ; Chen Y; Du W; Peng H; Wang R; Xia Y; Xin P; Wigle PR; Papadimitropoulos EA Value Health Reg Issues; 2016 May; 9():93-98. PubMed ID: 27881268 [TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis. Kourlaba G; Fragoulakis V; Maniadakis N Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992 [TBL] [Abstract][Full Text] [Related]
19. Direct healthcare costs and resource consumption after acute coronary syndrome: a real-life analysis of an Italian subpopulation. Roggeri DP; Roggeri A; Rossi E; Cinconze E; De Rosa M; Maggioni AP; Eur J Prev Cardiol; 2014 Sep; 21(9):1090-6. PubMed ID: 23515447 [TBL] [Abstract][Full Text] [Related]
20. Costs of payment in Thai acute coronary syndrome patients. Moleerergpoom W; Kanjanavanit R; Jintapakorn W; Sritara P J Med Assoc Thai; 2007 Oct; 90 Suppl 1():21-31. PubMed ID: 18431883 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]